证券代码：833230 证券简称：欧康医药 公告编号：2024-011 成都欧康医药股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《中华人民共和国公司法》、《公司章程》及《利润分配管理制度》等相 关规定，成都欧康医药股份有限公司（以下简称"公司"）为积极履行回报股东 义务，与全体股东分享公司经营收益，在统筹考虑战略发展目标及流动资金需求， 保证公司健康、稳定、持续发展的前提下，公司拟实施 2023 年年度权益分派。 一、权益分派预案情况 三、公司章程关于利润分配的条款说明 根据《公司章程》规定，公司利润分配政策包括： 根据公司 2024 年 4 月 17 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 94,643,346.54 元，母公司未分配利润为 95,808,699.06 元。 公司本次权益分派预案如下：公司目前总股本为 75,631,404 股，以未分 ...

Financial Performance - The estimated net profit attributable to shareholders for 2023 is expected to be 18.24 million yuan, a decrease of 45.82% compared to the same period last year, which was 33.66 million yuan [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be 14.23 million yuan, a decrease of 54.89% compared to the same period last year [4]. - The decline in net profit is attributed to intensified competition in the plant extraction industry and price reductions to maintain market share [5]. Sales and Market Trends - Sales revenue from the quercetin product line decreased by 57.67% due to weak market demand and significant price drops [5]. - The company experienced a 21.56% year-on-year increase in sales revenue in Q4 2023, indicating a gradual recovery in business operations [5]. Strategic Plans - The company plans to leverage its domestic GMP certification and food production licenses to expand into the domestic raw materials and food markets in 2024 [5]. - The company aims to optimize its product structure and enhance service capabilities to improve core competitiveness and profitability [5]. Investment Caution - The company emphasizes the importance of cautious investment decisions as the financial data for 2023 is preliminary and unaudited [6].

Financial Performance - In 2023, the company reported operating revenue of CNY 242,799,574.73, a decrease of 9.89% compared to the previous year[2] - The net profit attributable to shareholders was CNY 18,238,455.70, down 45.82% year-on-year[2] - The net profit after deducting non-recurring gains and losses was CNY 14,232,236.04, a decline of 54.89% compared to the previous year[2] - The basic earnings per share decreased to CNY 0.24, down 57.89% year-on-year[2] Assets and Investments - Total assets at the end of the reporting period were CNY 448,229,584.83, an increase of 1.76% from the beginning of the year[3] Future Plans and Projects - The company plans to complete the "Technological Transformation and Capacity Expansion Project (Phase I)" by mid-2024, aiming to enhance production efficiency through automation and digitalization[4] - The U.S. subsidiary's establishment is nearly complete, with plans to strengthen market expansion in the U.S. in 2024[5] - The company aims to enhance its competitive edge through product development and expand both domestic and international markets in 2024[5] Product Development - The product "Diosmin" has passed GMP compliance checks and is expected to be sold in the domestic market in 2024[5] - The company obtained 8 food production licenses in 2023, allowing for further development in the domestic food raw material market in 2024[5]

证券代码：833230 证券简称：欧康医药 公告编号：2024-002 成都欧康医药股份有限公司 关于获得 2023 年四川省节水型企业的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、基本情况 成都欧康医药股份有限公司（以下简称"公司"）近日收悉四川省经济和信 息化厅与四川省水利厅下发的《关于发布 2023 年省级节水型企业名单的通知》 （川经信环资函[2024]83 号），公司经过相关程序审定，获得 2023 年四川省节 水型企业称号。 二、对公司的影响 公司获得"2023 年四川省节水型企业"称号是对公司在节约用水工作中取 得成绩的肯定，是政府给予公司的一种荣誉。公司首先在生产经营管理上厉行节 约，努力提高公司节水管理水平和用水效率，发挥全体员工在节约用水、保护生 态环境中的引领作用，促进工业绿色低碳循环发展；同时促进用水的科学性与合 理性，深挖节水潜力，以管理抓节水、以制度促节水，积极采用节水新技术、新 工艺、新设备，淘汰落后用水工艺、设备器具等，减少了水资源的浪费，可降低 生产成本； ...

| | 公告日期 2024-02-06 异常期间 无 | | | | | --- | --- | --- | --- | --- | | | 欧康医药(833230) 连续竞价 1669649 （股） | 成交数量 | 成交金额（万 元） | 1749.83 | | | 当日价格振幅达到30%的前5只股票 涉及事项 | | | | | 买/卖 | 营业部或交易单元名称 | | 买入金额（元） | 卖出金额（元） | | 买1 | 海通证券股份有限公司舟山海山路营业部 | | 495754.04 | 0 | | 买2 | 国盛证券有限责任公司常州武青路营业部 | | 424924 | 0 | | 买3 | 招商证券股份有限公司深圳福华三路证券营业部 | | 408953.29 | 21820 | | 买4 | 兴业证券股份有限公司上海陆家嘴证券营业部 | | 401918.7 | 0 | | 买5 | 国信证券股份有限公司深圳罗湖人民南路证券营业部 | | 349765.2 | 0 | | 卖1 | 财达证券股份有限公司邢台郭守敬北路营业部 | | 0 | 1010804.75 | | 卖2 | 申万宏源西部证 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-02- | | | | | 异常期间涨跌幅偏离值累计 | | 06 | 833454 | 同心传动 | 40358281.0 | 46105.5 | 达到63.58% | | 2024-02- | 837663 | 明阳科技 | 18864500.0 | 24413.58 | 异常期间涨跌幅偏离值累计 | | 06 | | | | | 达到51.32% | | 2024-02- | 873570 | 坤博精工 | 2748272 | 11043.36 | 当日收盘价涨幅达到30.00% | | 06 | | | | | | | 2024-02- | | 九菱科技 | | | 当日收盘价涨幅达到29.99% | | 06 | 873305 | | 3389123 | 5593.54 | | | 2024-02- | 833454 | 同心传动 | 22575674.0 | 29572.71 | 当日收盘价涨幅达到29.97% | | ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-001 一、本次签字注册会计师变更情况 中汇会所作为公司 2023 年度审计机构，原委派陈颖轩为项目合伙人及签字 注册会计师、蔡晓颖为签字注册会计师、谢贤庆为质量控制复核人为公司提供 2023 年度审计服务。因原签字注册会计师蔡晓颖离职，中汇会所现委派陈颖轩、 罗显菊、余丽为签字注册会计师，谢贤庆为质量控制复核人，继续完成公司 2023 年度财务报告审计相关工作。 成都欧康医药股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 成都欧康医药股份有限公司（以下简称"公司"）于 2023 年 4 月 11 日召开 第三届董事会第十七次会议，审议通过《关于续聘会计师事务所的议案》，同意 续聘中汇会计师事务所（特殊普通合伙）（以下简称"中汇会所"）为公司 2023 年度审计机构，该议案已于 2023 年 5 月 9 日经公司 2022 年年度股东大会审议 通过。具体内容详见公司于 2023 年 4 月 13 ...

Product Overview - Quercetin is primarily used in health supplements abroad, with functions including immune enhancement, antioxidant, anti-inflammatory, and antibacterial effects [3] - Quercetin has shown resistance to coronavirus and improvement effects on pulmonary fibrosis and nodules [3] - The product is mainly sold abroad due to domestic regulatory restrictions [3] - The company is developing high-quality quercetin products for functional beverages and food additives [3] - Efforts are being made to expand the European market and prepare for domestic market entry [3] Market and Pricing - Quercetin prices rose due to increased demand for its anti-coronavirus and anti-inflammatory effects, coupled with a significant reduction in raw material Sophora japonica in 2021 [4] - Prices normalized in 2022 after a good harvest of Sophora japonica [4] - Current price reductions may lead to decreased sales revenue and profits, but long-term demand remains strong [4] - If Sophora japonica does not experience a significant reduction in 2024, quercetin prices are expected to remain stable [4] Synthetic Biology - Synthetic biology involves using biotechnology to construct microbial strains for producing target substances, offering advantages such as safety, low environmental impact, and cost-effectiveness in mass production [5] - The process includes five stages: product selection, strain development, engineering strain experiments, production, and product application promotion [5] - The company has strong technical advantages in target substance purification and refinement, with a high market share in Europe, the US, Japan, and Australia [5] - Collaboration with Jiangsu Haifei leverages the company's expertise in plant extraction and Haifei's strengths in biological fermentation equipment and engineering [5] - Cost reductions through synthetic biology could theoretically reach up to one-third, depending on market demand [6] - Several product selections are currently under joint development, with progress updates to be disclosed as per regulatory requirements [6] Global Market and Applications - Quercetin is primarily used in health supplements abroad, including functional foods and dietary supplements [7] - The US Pharmacopoeia has included quercetin, and the company has completed product process development meeting US Pharmacopoeia standards [7] - The company is conducting research for quercetin's application as a new food ingredient in China [7] - In 2023, the company completed the development of water-soluble quercetin and other new products, and obtained SC certificates for domestic market development [8] - Approximately 70% of global quercetin supply comes from China, though there are no official statistics [9] Financial and Product Performance - In the first three quarters of 2023, the company's Citrus aurantium series had higher gross margins than the Sophora japonica series, with diosmin accounting for over 20% of the company's revenue [9] - Diosmin is used in pharmaceuticals, health supplements, and cosmetics, with benefits including reducing vascular fragility and abnormal permeability, enhancing venous tension, and improving vascular stability [9] - The company's diosmin raw material has passed GMP compliance inspections, enabling broader domestic and international market sales [9] - The company has obtained SC certificates for 8 products, including neohesperidin dihydrochalcone, and is preparing for domestic market development [9]

| | 公告日期 2023-12-26 无 | 异常期间 | | | | | --- | --- | --- | --- | --- | --- | | | 欧康医药(833230) 连续竞价 | 成交数量 （股） | 9644624 | 成交金额（万 元） | 15528.73 | | | 涉及事项 当日换手率达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | 3285552.16 | 2255443.72 | | 买2 | 东方财富证券股份有限公司拉萨金融城南环路证券营业部 | | | 2630458.85 | 388980.15 | | 买3 | 东方财富证券股份有限公司拉萨东城区江苏大道证券营业部 | | | 2436546.82 | 688499.25 | | 买4 | 国信证券股份有限公司深圳互联网分公司 | | | 2332587.53 | 1851843.47 | | 买5 | 中泰证券股份有限公司慈溪新城大道证券营业部 | | | 20 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2023-12- | 871642 | 通易航天 | 46180131.0 | 64630.65 | 异常期间涨跌幅偏离值累计 | | 26 | | | | | 达到53.84% | | 2023-12- | | 康乐卫士 | | | 异常期间涨跌幅偏离值累计 | | 26 | 833575 | | 28624162.0 | 66065.99 | 达到42.81% | | 2023-12- | | 恒进感应 | | | 异常期间涨跌幅偏离值累计 | | 26 | 838670 | | 25936137.0 | 33395.9 | 达到40.06% | | 2023-12- | | 康乐卫士 | | | 当日收盘价涨幅达到30.00% | | 26 | 833575 | | 17261221.0 | 43647.75 | | | 2023-12- | 831526 | 凯华材料 | 14371743.0 | 37995.61 | 当日收盘价涨幅 ...